文献速递MDS 与骨髓增殖性肿瘤白血病

DNA修复基因胚系变异(含BRCA1/2)可能致家族性骨髓增殖性肿瘤

Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms.
PubMed 文献 · Blood Adv · 2021-01-01

为探寻骨髓增殖性肿瘤(MPN)的遗传易感因素,研究者对5个携带体细胞JAK2 V617F突变的家族(含亲子或同胞患病对)行全外显子测序。在4个家族中检出DNA修复通路已知肿瘤易感基因的罕见胚系变异,包括高外显率BRCA1和BRCA2。2例ET或PV患者进展为急性髓系白血病,提示此类家族性MPN白血病转化风险可能较高。

要点

  • 约7%–8%的MPN患者携带可导致驱动突变的易感胚系变异。
  • 家族性MPN中可检出DNA修复通路基因(含BRCA1/2)罕见胚系变异。
  • 检出胚系变异者可能扩展肿瘤谱,并提示PARP抑制剂等新治疗选择。

核心结论

  • DNA修复通路基因(包括BRCA1和BRCA2)的罕见胚系变异可能与家族性MPN相关。

研究设计与样本

  • 对5个携带体细胞JAK2 V617F突变、含亲子或同胞患病对的MPN家族行全外显子测序。

主要发现

  • 在4个家族中检出DNA修复通路已知肿瘤易感基因的罕见胚系变异,包括高外显率BRCA1和BRCA2。
  • 2例ET或PV患者进展为急性髓系白血病,提示此类家族性MPN白血病转化风险可能较高。
  • 约7%至8%的MPN患者携带可导致驱动突变、增强JAK-STAT信号的易感胚系变异。

临床怎么用

  • 对家族性MPN可考虑行胚系基因诊断以明确病因。
  • 检出DNA修复通路胚系变异者需关注更广的肿瘤谱及预防性管理。
  • PARP抑制剂等可能成为MPN的新治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The molecular causes of myeloproliferative neoplasms (MPNs) have not yet been fully elucidated. Approximately 7% to 8% of the patients carry predisposing genetic germline variants that lead to driver mutations, which enhance JAK-STAT signaling. To identify additional predisposing genetic germline variants, we performed whole-exome sequencing in 5 families, each with parent-child or sibling pairs affected by MPNs and carrying the somatic JAK2 V617F mutation. In 4 families, we detected rare germline variants in known tumor predisposition genes of the DNA repair pathway, including the highly penetrant BRCA1 and BRCA2 genes. The identification of an underlying hereditary tumor predisposition is of major relevance for the individual patients as well as for their families in the context of therapeutic options and preventive care. Two patients with essential thrombocythemia or polycythemia vera experienced progression to acute myeloid leukemia, which may suggest a high risk of leukemic transformation in these familial MPNs. Our study demonstrates the relevance of genetic germline diagnostics in elucidating the causes of MPNs and suggests novel therapeutic options (eg, PARP inhibitors) in MPNs. Furthermore, we uncover a broader tumor spectrum upon the detection of a germline mutation in genes of the DNA repair pathway.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Elbracht M, Meyer R, Kricheldorf K, et al. Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms. Blood Adv. 2021. PMID: 34477817. doi:10.1182/bloodadvances.2021004811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。